Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India
Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury shares) at CHF 44.31 per share, representing an equity value of approximately CHF 1.46 billion....
Cambrex Advances US and European Expansions
EAST RUTHERFORD, N.J., March 23, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the completion of initial engineering studies for its new, large-scale active pharmaceutical...
Lifespan Vision Ventures Co-Leads Sift Biosciences' $3.7M Pre-Seed Financing
NORWALK, Conn., Feb. 19, 2026 /PRNewswire/ -- Lifespan Vision Ventures, an investment firm focused on therapeutics that improve human healthspan, today announced that it has co-led Sift Biosciences' oversubscribed $3.7 million Pre-Seed financing...